10-K: Acutus Medical Navigates Restructuring and Delisting in Fiscal Year 2024, Focuses on Medtronic Partnership

Acutus Medical's 2024 10-K filing reveals a company in transition, marked by strategic restructuring, operational downsizing, and delisting from Nasdaq, as it focuses on its manufacturing partnership with Medtronic.

Summary

• Acutus Medical's 10-K filing for fiscal year 2024 details a period of significant change, including a strategic restructuring to focus on manufacturing left-heart access products for Medtronic.
• The company underwent an operational downsizing, reducing its workforce by approximately 70% to align with its new strategic direction.
• Acutus Medical's common stock was delisted from Nasdaq and began trading over-the-counter.
• The company filed a Form 15 with the SEC to deregister its common stock and suspend its reporting obligations under the Exchange Act.
• Revenue for the year ended December 31, 2024, was $20.2 million, compared to $7.2 million in 2023, primarily due to increased sales of left-heart access products to Medtronic.
• Net loss from continuing operations was $4.5 million in 2024, compared to $11.9 million in 2023.
• The company earned $11.1 million related to Net Sales Earnouts in 2024 and received $18.7 million in related payments.
• As of December 31, 2024, Acutus Medical had U.S. federal and state net operating loss carryforwards of approximately $458.7 million and $150.1 million, respectively.
• The company amended its debt agreement with Deerfield Funds to allow for deregistration and modified financial reporting requirements.
• Acutus Medical anticipates its sole source of revenue will be potential earnouts from Medtronic's sales of left-heart access products through 2027.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While revenue increased, the company is undergoing significant restructuring and faces delisting, indicating a challenging situation with limited future prospects.

Positives

• Revenue increased significantly in 2024 due to the Medtronic partnership.
• Net loss from continuing operations decreased in 2024.
• The company successfully earned and received payments related to Net Sales Earnouts.
• Acutus Medical amended its debt agreement to facilitate deregistration and adjust financial reporting requirements.
• The company has significant net operating loss carryforwards that could be used to offset future taxable income.

Negatives

• Acutus Medical's common stock was delisted from Nasdaq.
• The company filed a Form 15 with the SEC to deregister its common stock and suspend its reporting obligations under the Exchange Act.
• The company is heavily reliant on Medtronic for revenue generation.
• There is a risk that Medtronic may not be able to successfully market and sell the Products.
• The company has a significant accumulated deficit.

Risks

• Acutus Medical is heavily dependent on Medtronic for all of its revenue, with no sales or marketing capabilities of its own.
• The company's ability to continue to have the liquidity necessary to service its debt and meet contractual payment obligations and fund its operations depends on many factors.
• The board of directors may decide to pursue a liquidation and dissolution of the business.
• Defects or failures associated with the Products manufactured for Medtronic may have a material adverse effect on the business.
• The company's common stock has been delisted from Nasdaq, and it has undertaken actions to effect a 'going dark' transaction.

Future Outlook

Acutus Medical anticipates that its sole source of revenue will be potential earnouts from Medtronic's sales of left-heart access products through 2027.

Management Comments

• The board of directors determined that going dark is in the best interests of the company and its stockholders due to substantial cost savings.
• Management believes that current cash, cash equivalents and marketable securities and anticipated cash earnouts generated from Medtronics sales of the Products are sufficient to fund operations for at least the next 12 months.

Industry Context

The medical device industry is intensely competitive, subject to rapid change, and significantly affected by new product introductions and other market activities of industry participants.

Comparison to Industry Standards

• Acutus Medical faces indirect competition from Medtronics competitors for heart access products in the electrophysiology field, including Abbott Laboratories, Biosense Webster Inc. (a Johnson & Johnson Company), and Boston Scientific Corporation.
• Many competitors in the manufacturing services industry and the electrophysiology field are large, well-capitalized companies with significantly greater market share and resources.

Legal Proceedings

• A securities class action lawsuit was dismissed with prejudice after the plaintiff voluntarily dismissed the appeal.
• A settlement agreement was reached with Biotronik Parties, terminating certain agreements and settling arbitration.

Related Party Transactions

• The company has a consulting agreement with the chairman of the board.
• The company has debt obligations under the 2022 Credit Agreement with related parties Deerfield Private Design Fund III, L.P. and Deerfield Partners, L.P.

Stakeholder Impact

• Stockholders face the risk of losing all or a significant portion of their remaining investment in the event of a liquidation, dissolution, or winding up.
• Employees have been impacted by workforce reductions as part of the strategic restructuring and operational downsizing.
• The company's ability to meet its obligations to Medtronic is critical for maintaining its revenue stream and potential earnouts.

Next Steps

• The company will continue contract manufacturing for Medtronic until it has fulfilled its obligations under the Asset Purchase Agreement and the Distribution Agreement.
• Acutus Medical expects to continue to minimize costs while capturing the value associated with potential earnout payments it is eligible to receive under the Asset Purchase Agreement until 2027.
• The company may continue to explore opportunities for the sale of its remaining intellectual property assets relating to its former mapping and ablation business.

Key Dates

Keywords

Medtronic, left-heart access products, restructuring, operational downsizing, delisting, earnouts, revenue, net loss, debt agreement, deregistration